2011
DOI: 10.1016/j.reumae.2011.11.002
|View full text |Cite
|
Sign up to set email alerts
|

Duration of Treatment With Etanercept and Motives for Discontinuation in a Cohort of Patients With Rheumatic Disease

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
1
0
1

Year Published

2013
2013
2020
2020

Publication Types

Select...
6

Relationship

1
5

Authors

Journals

citations
Cited by 6 publications
(2 citation statements)
references
References 16 publications
0
1
0
1
Order By: Relevance
“…8,10 There are currently few cases published in the literature of patients with SAPHO syndrome who were successfully treated with etanercept. 1,2,4,5,7 Etanercept therapy downregulated polymorphonuclear neutrophil functions and cytokine production, in line with the clinical effectiveness of this TNF-a antagonist, preventing the interaction of TNF with its receptors on immune effector cells to bind competitively and reversibly both circulating TNF and the membrane bound TNF. 1 Our case allows us to confirm that etanercept is a satisfactory therapeutic option for cases of SAPHO syndrome in which other systemic treatments have failed or are contraindicated.…”
Section: Discussionmentioning
confidence: 72%
“…8,10 There are currently few cases published in the literature of patients with SAPHO syndrome who were successfully treated with etanercept. 1,2,4,5,7 Etanercept therapy downregulated polymorphonuclear neutrophil functions and cytokine production, in line with the clinical effectiveness of this TNF-a antagonist, preventing the interaction of TNF with its receptors on immune effector cells to bind competitively and reversibly both circulating TNF and the membrane bound TNF. 1 Our case allows us to confirm that etanercept is a satisfactory therapeutic option for cases of SAPHO syndrome in which other systemic treatments have failed or are contraindicated.…”
Section: Discussionmentioning
confidence: 72%
“…Głównym wskazaniem do zastosowania etanerceptu są m.in. reumatoidalne zapalenia stawów (RZS), ZZSK, łuszczyca zwykła i łuszczycowe zapalenie stawów (16,17). Jest to lek ceniony przez reumatologów z powodu skuteczności działania.…”
Section: Etanerceptunclassified